menu
    • menu
    [{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bifikafusp alfa","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"L19TNF","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fibromun","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bifikafusp Alfa","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Philogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bifikafusp Alfa","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Merck & Co. Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Philogen \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Not Applicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"L19IL2","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Onfekafusp Alfa","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by Philogen

    Menu

    Philogen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sun Pharma, Philogen Ink Licensing Deal for Cancer Drug Firbomun

                            Details : The agreement aims for the commercialisation of Fibromun (onfekafusp alfa), being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.

                            Brand Name : Fibromun

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L19IL2,L19TNF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen and Sun Pharma seek EMA approval for melanoma therapy

                            Details : Announced the filing of a marketing authorisation application with the European Medicines Agency for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 04, 2024

                            Lead Product(s) : L19IL2,L19TNF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onfekafusp Alfa,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen Updates on Ph III Trial of Onfekafusp Alfa in Advanced Soft Tissue Sarcoma

                            Details : L19TNF (onfekafusp alfa), a homotrimer peptide fused to human TNF, is being evaluated with doxorubicin for first-line treatment of advanced or metastatic soft tissue sarcoma.

                            Brand Name : L19TNF

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 20, 2024

                            Lead Product(s) : Onfekafusp Alfa,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nidlegy™ Phase III PIVOTAL Trial Meets the Study’s Primary Objective in Patients with Locally Advanced Ful...

                            Details : Nidlegy (bifikafusp alfa & onfekafusp alfa) is designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration.

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 16, 2023

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Philogen Announces Clinical Trial Collaboration with MSD

                            Details : Under the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy (bifikafusp alfa) in a randomized Phase II clinical trial in unresect...

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sun Pharma and Philogen Sign Licence Agreement for Anti-Cancer Therapy

                            Details : Under the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy (bifikafusp alfa), a new anti-cancer biopharmaceutical, being developed by Philogen for melanoma and non-melanoma skin cancers, in the territories of Europe, Australia an...

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen Publishes New Data on A Fibromun-Based Treatment Combination in Science Translational Medicine in Col...

                            Details : L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and TNF. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs.

                            Brand Name : L19TNF

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 24, 2023

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen Announces Enrolment of 214 Patients in the Nidlegy™ Phase III European Clinical Trial For the Treat...

                            Details : Nidlegy (bifikafusp alfa) is combination of the immunocytokines L19IL2 and L19TNF, which is being developed as intralesional treatment for patients with advanced locoregional melanoma and non-melanoma skin cancers.

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2022

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen Receives Authorisation to Initiate New Study in France to Evaluate Nidlegy™ in Several Nonmelanoma ...

                            Details : Nidlegy™, the combination of the two active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF), has already shown promising results in the intralesional treatment of patients with advanced melanoma and in BCC and cSCC in an ongoing Phase ...

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 17, 2022

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Philogen

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Philogen Announces the Completion of A Second Interim Analysis of Its Phase III Clinical Program with Nidlegy ...

                            Details : Nidlegy, as a neoadjuvant was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated in PIVOTAL phase III trial in melanoma patients with locally advanced, fully resectable metastatic cancer.

                            Brand Name : Nidlegy

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 13, 2022

                            Lead Product(s) : Bifikafusp Alfa,Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth